Find your next paid study

Baylor College of MedicineNCT05355272

~$75 – $2,000

Actual pay is set by the research site.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Adenocarcinoma+7 more

Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and i…

Revolution Medicines, Inc.NCT07349537

Actual pay is set by the research site.

Healthy VolunteerOlder Adults (65-85 Years)

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.

University of Colorado, DenverNCT07516405

~$500 – $7,500

Actual pay is set by the research site.

Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more

Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1).

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

HER2-negative Breast CancerHormone Receptor Positive TumorAdvanced Breast Cancer+1 more

Actual pay is set by the research site.

Observational

A Phase 2 Study of TheraBionic P1 Device for Patients With Metastatic Hormone Positive Breast Cancer Post Endocrine Therapy

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer…

Barbara Ann Karmanos Cancer InstituteNCT07227831

~$10 – $1,125

Actual pay is set by the research site.

A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pem…

Advanced Solid Tumors

Pyxis Oncology, IncNCT06795412

Actual pay is set by the research site.

Phase 2

A Phase II Trial of Futibatinib in Combination With Durvalumab (MEDI4736) Administered to Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer Before Cystectomy

This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladde…

Bladder Urothelial CarcinomaMuscle Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8+1 more

T-Cell Leukemia/Lymphoma, AdultT-cell Leukemia/LymphomaT-cell Leukemia+1 more

~$75 – $3,000

Actual pay is set by the research site.

Yuanquan YangNCT06263153

Phase 2

A Phase 2 Study for Screening and Prevention of Adult T-cell Leukemia/Lymphoma With Mogamulizumab in High-Risk Carriers of HTLV-1

The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL…

Memorial Sloan Kettering Cancer CenterNCT06698003

~$75 – $2,000

Actual pay is set by the research site.

Carcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of the Head and NeckEsophageal Squamous Cell Carcinoma+5 more

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the s…

Seagen, a wholly owned subsidiary of PfizerNCT05208762

Actual pay is set by the research site.

Breast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This…

Reading DisabilityReading Problem

Actual pay is set by the research site.

Incyclix BioNCT05735080

Observational

The Role of Knowledge Retrieval in Inference-making Among Struggling Readers

This project will (a) examine the relationship between knowledge retrieval and inferencing; (b) determine the effectiveness of an intervention that improves kn…

William Jewell CollegeNCT05692973

~$10 – $750

Actual pay is set by the research site.

Phase 3

COMparative Prospective Assessment Through Clinically Integrated Randomized Trials Evaluating Intravesical Treatments: The COMPARE IT Trial

The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved…

Non-Muscle Invasive Bladder Cancer